# Vitamin K2 Market

> Vitamin K2 market Research Report Information By Product Type (MK-7 and MK-4 & Combination Drugs), By Source (Natural and Synthetic), By Form (Capsules & Tablets, Powder, and Oil), By Application (Nutraceutical and Food & Pharmaceutical), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 10.3%
- **2025:** USD 134.2 Million
- **2035:** USD 358.7 Million
- **Key Players:** Gnosis by Lesaffre, Balchem Corporation (Kappa Bioscience), J-Oil Mills, Inc., Kyowa Hakko Bio Co., Ltd., Viridis BioPharma Pvt. Ltd., Novonesis A/S, dsm-firmenich, GeneFerm Biotechnology Co., Ltd.

**Report ID:** MRFR/HC/6026-CR · **Pages:** 117 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** October 22, 2026

**URL:** https://www.marketresearchfuture.com/reports/vitamin-k2-market-7495

---

## Market Summary

According to MRFR analysis, the Vitamin K2 Market Size was valued at USD 122.29 Billion in 2024. The market is projected to grow from USD 127.82 Billion in 2025 to USD 198.88 Billion by 2035, registering a CAGR of 4.5% during the forecast period (2025–2035). North America dominated the market with the largest revenue share of 39.99% in 2024.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Ageing global population | +1.8% | Global, strongest in Japan, Europe, China | Long-term (≥4 yr) | [13][20][21] |
| Osteoporosis and fracture burden | +1.6% | North America, Europe, Japan | Long-term (≥4 yr) | [14] |
| Cardiovascular research momentum | +1.5% | North America, Europe | Medium-term (2–4 yr) | [15] |
| High supplement usage rates | +1.4% | North America | Short-term (≤2 yr) |  |
| Vitamin D3 and K2 co-formulation | +1.2% | Global | Short-term (≤2 yr) | [7] |
| Clear regulatory pathways | +0.9% | Europe, Asia-Pacific | Medium-term (2–4 yr) | [2][17][18] |
| Consolidation and synthetic scale-up | +0.8% | Global | Medium-term (2–4 yr) | [9][10] |

### Ageing Global Population

The slowest but most resilient growth lever is demographics. According to WHO projections, there will be 2.1 billion people over 60 by 2050 [13]. More than a quarter of the population in the EU is already 65 years of age or older [20], and by the end of 2024, there were more than 310 million people in China who were 60 years of age or older [21]. Compared to younger adults, older customers purchase bone and heart supplements at significantly higher prices, and this group is expected to grow each year.

### Osteoporosis and Fracture Burden

The original commercial rationale for K2 is still bone health. According to the International Osteoporosis Foundation, one in five men and one in three women over 50 may experience an osteoporotic fracture [14]. 180 mcg of daily MK-7 helped prevent age-related bone loss in healthy postmenopausal women, according to a three-year Dutch experiment . This study, which is widely cited by brands, supports the 90–180 mcg dose found in the majority of final products.

### Cardiovascular Research Momentum

Interest in arterial health is widening the buyer base beyond bone-focused consumers. Cardiovascular disease caused about 20.5 million deaths in 2021, according to the World Heart Federation [15]. A randomized trial reported that three years of MK-7 supplementation improved arterial stiffness in postmenopausal women . Heart-health claims now appear on a growing share of K2 labels, particularly in combination products marketed to adults over 50.

### High Supplement Usage Rates

North America provides the deepest consumer pool. The Council for Responsible Nutrition's 2024 survey found that roughly three in four US adults use dietary supplements . That habit lowers the barrier for K2 adoption, because shoppers already buying vitamin D or calcium can trade up to combination formulas. Retailers report K2 as one of the more consistent growth lines inside the vitamins aisle.

### Vitamin D3 and K2 Co-Formulation

Pairing K2 with vitamin D3 has become a default formulation choice. Research shows MK-7 has a half-life of around three days, producing stable blood levels with once-daily dosing [7], while nutritional doses of MK-4 were not detectable in serum in a comparative study . That pharmacokinetic gap explains why D3-plus-MK-7 SKUs dominate new launches and pull MK-7 volumes upward.

### Clear Regulatory Pathways

Regulatory clarity reduces launch risk for brands. EFSA assessed MK-7 as a source of vitamin K for foods and supplements in 2008 [2], giving European formulators an early green light. India's FSSAI consolidated nutraceutical rules in 2022 [18], and Japan's Foods with Function Claims system lets companies notify evidence-backed claims without full drug approval [17]. These frameworks shorten time to market in fast-growing regions.

### Consolidation and Synthetic Scale-Up

Ownership changes have put deeper pockets behind the leading ingredient brands. Gnosis by Lesaffre combined vitaMK7 and MenaQ7 through its 2021 acquisition of NattoPharma [10], and Balchem paid about USD 338 Million for Kappa Bioscience in 2022 [9]. Both owners have since funded capacity, clinical work and distribution, which supports supply reliability for large multinational supplement brands.

## Restraints

## Restraints Impact Analysis

Restraint impacts are directional estimates of downward pressure on Vitamin K2 Market growth. They interact with drivers and should not be subtracted directly from the CAGR.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Mixed outcomes in clinical trials | −0.9% | North America, Europe | Medium-term (2–4 yr) | [22] |
| No separate intake reference for K2 | −0.7% | Global | Long-term (≥4 yr) | [1][3] |
| Anticoagulant interaction concerns | −0.6% | Global | Long-term (≥4 yr) | [1] |
| Stability losses in mineral formulas | −0.6% | Global | Short-term (≤2 yr) | [23] |
| Tighter ingredient compliance scrutiny | −0.5% | North America | Short-term (≤2 yr) |  |

### Mixed Outcomes in Clinical Trials

The cardiovascular narrative is not supported by every trial. 720 mcg of MK-7 plus vitamin D did not significantly delay the progression of aortic valve calcification over a two-year period, according to the Danish AVADEC trial [22]. These kinds of results limit how aggressively brands may market heart advantages since they provide cautious doctors a reason to defer recommendations and give regulators a reason to reject disease-adjacent claims.

### No Separate Intake Reference for K2

Instead of establishing dietary guidelines for menaquinones specifically, health authorities do so for vitamin K in general. Without differentiating between K1 and K2, EFSA's 2017 decision established an appropriate daily intake of 70 mcg for adults [3], and US adequate intakes of 90–120 mcg follow the same methodology [1]. Brands find it difficult to convey deficiencies in the absence of a K2-specific statistic, and mass-market customers frequently believe leafy greens meet their demands.

### Anticoagulant Interaction Concerns

Vitamin K interferes with warfarin and similar vitamin K antagonists, and NIH guidance advises consistent intake for patients on these drugs [1]. That warning appears on labels and in pharmacist counseling. It narrows the addressable population among older adults, precisely the cohort with the highest cardiovascular risk, and makes some retailers reluctant to promote K2 at pharmacy counters.

### Stability Losses in Mineral Formulas

MK-7 degrades when blended with calcium, magnesium and other minerals. Kappa Bioscience reported low MK-7 recovery after testing more than 100 finished-product samples [23]. Degradation forces manufacturers to overage or pay for encapsulated grades, which raises cost per dose. Brands that skip these steps risk label-claim failures in third-party testing.

### Tighter Ingredient Compliance Scrutiny

US regulators have sharpened expectations on ingredient documentation. FDA's 2024 guidance on new dietary ingredient notification procedures clarified filing timelines and content expectations . Smaller importers of low-cost MK-7 face higher compliance costs, and buyers are demanding fuller certificates of analysis, including cis-isomer content, before onboarding new suppliers.

## Opportunities

## Vitamin K2 Market Opportunities

The following opportunities represent the most actionable growth pockets for participants in the Vitamin K2 Market over the forecast period.

### Fortification of Everyday Foods and Beverages

Encapsulated MK-7 grades now survive heat and mineral exposure, opening dairy, plant-based milks, bars and juices to fortification [23]. Food formats reach consumers who never enter the supplement aisle. Suppliers that pair stability data with application support for food technologists can capture this segment early, where the powder format already leads.

### Emerging-Market Expansion in India and Brazil

India's 2022 nutraceutical regulations created a defined route for K2 products [18], and its rapidly growing urban middle class is adopting bone and heart supplements. Brazil offers similar dynamics in South America. Local fermentation capacity, regional pricing and pharmacy-chain partnerships could convert these markets from low base to double-digit growth.

### Biomarker-Linked and Subscription Business Models

Blood markers of vitamin K status, such as undercarboxylated osteocalcin, allow personalized dosing. Direct-to-consumer brands can bundle at-home testing with K2 subscriptions, generating recurring revenue and anonymized status data. That data can be monetized through insights sold to formulators and used to substantiate claims.

### Sports and Women's Health Positioning

Ingredient brands are reaching new demographics through athletic sponsorship. Balchem's 2025 partnership linking K2VITAL to FC Bayern Women targets younger, active consumers and female athletes [12]. Peri-menopause and bone-building products aimed at women aged 35–55 represent a sizable, underserved audience.

## Future Outlook

## Vitamin K2 Market Future Outlook

Four themes will define how the Vitamin K2 Market evolves over the coming decade.

### Precision Fermentation and Synthesis

Production will shift further toward engineered fermentation strains and patented synthetic routes that deliver near-pure all-trans MK-7. Suppliers already market 99.7% all-trans material [9], and the gap between premium and commodity grades will widen. Producers that cut cost per gram while holding purity will win large multinational contracts.

### Biomarker-Guided Nutrition

Testing for vitamin K status is moving from research labs into consumer kits. As testing costs fall, brands will tailor doses to measured need rather than generic label amounts. This shift favors companies with clinical datasets and will strengthen the evidence base for cardiovascular K2 nutrition, an area where current trial results remain mixed [22].

### The Healthy Ageing Economy

Population ageing will intensify through 2035. WHO expects the 60-plus population to double to 2.1 billion by 2050 [13], and Eurostat data show Europe's old-age share rising steadily [20]. Products that address mobility, bone density and arterial health together will capture the largest share of spending by older adults.

### Clean Label and Supply Traceability

Consumers and retailers increasingly demand proof of origin, allergen-free substrates and sustainable manufacturing. Expect wider use of batch-level traceability, third-party purity certification and vegan claims. Synthetic suppliers will counter natural-source marketing with stability and consistency data, keeping both camps competitive.

## Segment Insights

## Vitamin K2 Market Segmentation

### By Product Type

The Vitamin K2 Market by product type covers Menaquinone-7 (MK-7), Menaquinone-4 (MK-4) and Others.

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Menaquinone-7 (MK-7) | 64.5% share | Long half-life, once-daily dosing |
| Menaquinone-4 (MK-4) | USD 33.3 Million | Prescription osteoporosis use in Japan |
| Others | 8.6% CAGR | Full-spectrum MK-6, MK-7 and MK-9 blends |

Menaquinone-7 (MK-7) dominates and is also the fastest-growing product type because it stays active in the body for days, allowing microgram-level daily doses [7]. Menaquinone-4 (MK-4) retains a strong pharmaceutical niche, with Japan prescribing 45 mg daily doses for osteoporosis, but its short half-life limits consumer supplement use . The Others category, including MK-9 and full-spectrum blends, appeals to brands seeking differentiation on premium shelves.

### By Source

The Vitamin K2 Market by source divides into Natural and Synthetic material.

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Natural | 62.6% share | Clean-label and fermentation-derived positioning |
| Synthetic | 12.0% CAGR | Batch consistency, purity, scalable supply |

Natural K2, produced by fermentation, leads because consumers associate it with traditional foods such as natto and with clean-label values. Synthetic K2 is growing faster as pharmaceutical buyers and large supplement brands prioritize predictable potency, high all-trans purity and supply security [9]. Advances in synthesis have narrowed the cost gap, and synthetic producers now emphasize identity with the bioactive natural molecule to counter consumer skepticism.

### By Form

The Vitamin K2 Market by form comprises Powder and Oil.

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Powder | 50.9% share | Tablets, capsules and dry blends |
| Oil | 11.9% CAGR | Softgels and liquid drops |

Powder leads because it suits tablets, capsules, gummies and fortified dry mixes, and encapsulated powder grades protect MK-7 from mineral-driven degradation [23]. Oil is the faster-growing form, carried by softgels and liquid drops that pair naturally with oil-based vitamin D3. Consumers who dislike swallowing tablets, including children and older adults, are pushing liquid formats into mainstream retail.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 38.6% share | D3 and K2 combinations, practitioner channels, e-commerce |
| Europe | 29.4% share | Novel food compliance, clean-label sourcing, pharmacy retail |
| Asia-Pacific | 11.8% CAGR | Natto heritage, ageing demographics, cross-border e-commerce |
| South America | USD 7.5 Million | Pharmacy chain expansion, local manufacturing |
| Middle-East and Africa | USD 5.1 Million | Premium imports, vitamin D deficiency awareness |
| Total | USD 134.2 Million | — |

Regional performance in the Vitamin K2 Market varies with supplement culture, dietary habits and regulatory maturity. North America leads on value, while Asia-Pacific leads on growth.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| United States | 84.2% of region | Mass retail, D3 and K2 combination products |
| Canada | 10.6% CAGR | Natural health product licensing |
| Rest of North America | USD 2.9 Million | Imported finished supplements |

The United States drives regional demand, supported by widespread supplement use  and a strong practitioner channel where exclusive professional-grade K2 lines have existed since 2017 [25]. Canada follows with natural health product licensing that favors documented ingredients. Distributor networks give contract manufacturers fast access to branded MK-7, and online retail now accounts for a growing share of new customer acquisition across the Vitamin K2 Market in this region.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 24.1% of region | Pharmacy retail, ageing population |
| United Kingdom | USD 7.1 Million | Online supplement sales |
| France | 14.6% of region | Bone health awareness among women |
| Italy | 9.4% CAGR | Pharmacy and parapharmacy growth |
| Spain | USD 3.4 Million | Healthy ageing campaigns |
| Rest of Europe | 22.8% of region | Nordic ingredient production, Eastern European demand |

Europe benefited from EFSA's early assessment of MK-7 [2], and Norway remains home to two of the most recognized ingredient brands [9][10]. Germany leads on pharmacy-driven sales, while the United Kingdom shows strong online demand. Authorized EU vitamin K claims covering bone maintenance and blood clotting [24] give brands a compliant messaging base, although cardiovascular claims stay restricted.

### Asia-Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 31.5% of region | Ageing population, cross-border e-commerce |
| Japan | USD 9.6 Million | Natto heritage, prescription MK-4 |
| India | 13.4% CAGR | Nutraceutical regulation, urban middle class |
| South Korea | 9.2% of region | Premium health functional foods |
| Rest of Asia-Pacific | USD 4.8 Million | Australia and Southeast Asian retail |

Japan anchors the region through natto consumption and prescription MK-4 for osteoporosis, while its Foods with Function Claims system supports consumer products [17]. China's large elderly population [21] and cross-border e-commerce are accelerating MK-7 uptake. India is the fastest-growing country, helped by FSSAI's 2022 framework [18], and South Korea favors premium imported formulas.

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 58.4% of region | Pharmacy chain distribution |
| Argentina | 9.8% CAGR | Improving supplement registration |
| Rest of South America | USD 1.6 Million | Chile and Colombia retail growth |

Brazil dominates regional consumption through large pharmacy chains that increasingly stock imported and locally blended K2 products. Argentina grows from a smaller base as supplement registration processes become more predictable. Currency volatility remains the main obstacle, pushing brands toward local manufacturing and smaller pack sizes to protect affordability.

### Middle-East and Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 27.5% of region | Vitamin D deficiency awareness |
| UAE | 11.2% CAGR | Premium imports, re-export hub |
| South Africa | USD 1.1 Million | Organized supplement retail |
| Rest of Middle-East and Africa | 33.0% of region | Gradual pharmacy expansion |

Gulf markets lead regional demand, where high rates of vitamin D deficiency have made D3 and K2 combinations a natural pharmacy upsell. Saudi Arabia benefits from health-focused national programs, and the UAE serves as a re-export hub. South Africa offers the most developed supplement retail sector in sub-Saharan Africa.

## Competitive Benchmarking

## Competitive Benchmarking

The Vitamin K2 Market is concentrated at the ingredient tier, with the top five suppliers holding an estimated 60–65% of revenue and an HHI estimated at 1,250–1,400. Two Norwegian-rooted platforms, now owned by Gnosis by Lesaffre and Balchem, set purity and clinical benchmarks [9][10]. Japanese producers lead MK-4 and natto-derived material, while a long tail of Chinese and Indian manufacturers competes on price for commodity MK-7.

| Company | Est. Revenue Share Range | Key Offerings for Vitamin K2 Market | Strategic Positioning |
| --- | --- | --- | --- |
| Gnosis by Lesaffre | ~22–27% | MenaQ7 and vitaMK7 natural and synthetic MK-7 | Clinical research leader with fermentation scale |
| Balchem Corporation (Kappa Bioscience) | ~20–25% | K2VITAL all-trans synthetic MK-7, K2VITAL Delta | Patented synthesis, encapsulation, US distribution |
| J-Oil Mills, Inc. | ~6–9% | Natto-derived MK-7 | Japanese heritage and food-grade supply |
| Kyowa Hakko Bio Co., Ltd. | ~4–6% | Fermentation-based nutritional ingredients | Pharmaceutical-grade quality systems |
| Viridis BioPharma Pvt. Ltd. | ~3–5% | MK-7 powders and oils | Cost-competitive Indian production |
| Novonesis A/S | ~2–4% | Fermentation and enzyme technologies | Biotech platform partnerships |
| dsm-firmenich | ~2–4% | Vitamin premixes including K2 | Global premix and fortification reach |
| GeneFerm Biotechnology Co., Ltd. | ~2–3% | Fermented MK-7 | Taiwan-based fermentation specialist |
| Vesta Nutra | ~1–3% | MK-7 ingredients for supplements | Contract manufacturer supply |
| Seebio Biotech | ~1–3% | Synthetic and fermented MK-7 | Price-led Chinese exporter |
| GF Fermentech | ~1–2% | Fermentation-derived vitamins | Regional fermentation capacity |

## Recent News & Developments

## Recent News & Developments

Recent activity in the Vitamin K2 Market centers on partnerships, consumer marketing and regulatory clarification.

- World Heart Federation (May 2023): Published the World Heart Report 2023, putting cardiovascular deaths at about 20.5 million in 2021 and reinforcing the heart-health case for K2 products [15]
- U.S. FDA (March 2024): Issued guidance on new dietary ingredient notification procedures, raising documentation expectations for K2 ingredient importers
- Gnosis by Lesaffre and SunWay Biotech (March 2024): Launched MenaQ7 Metabolic through a fermentation partnership, extending K2 into metabolic health positioning [11]
- WHO (October 2024): Updated its ageing fact sheet projecting 2.1 billion people aged 60+ by 2050, underscoring long-term demand [13]
- Council for Responsible Nutrition (2024): Survey showed roughly three in four US adults use supplements, confirming a deep buyer pool for combination products
- Balchem Corporation (February 2025): Filed its 2024 annual report detailing its human nutrition and health segment, which houses the K2VITAL business [8]
- Balchem Corporation (February 2025): Announced a multi-year K2VITAL partnership with FC Bayern Women to build consumer awareness among active women [12]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | The Vitamin K2 Market covers MK-7, MK-4 and other menaquinone ingredients from natural and synthetic sources, in powder and oil forms, sold for supplements, foods, pharmaceuticals and animal nutrition. |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 134.2 Million |
| Market Size in 2035 | USD 358.7 Million |
| CAGR (2026–2035) | 10.3% |
| Fastest Growing Segments | Synthetic (12.0% CAGR); Oil (11.9% CAGR); Asia-Pacific (11.8% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Gnosis by Lesaffre, Balchem Corporation (Kappa Bioscience), J-Oil Mills Inc., Kyowa Hakko Bio Co. Ltd., Viridis BioPharma Pvt. Ltd., Novonesis A/S, dsm-firmenich, GeneFerm Biotechnology Co. Ltd., Vesta Nutra, Seebio Biotech, GF Fermentech |
| Valuation Currency | USD Million |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: What purity specification should buyers request when sourcing for the Vitamin K2 Market?**
A: Request all-trans MK-7 content of at least 98–99%, with cis-isomer levels reported on every certificate of analysis. Cis isomers have little biological activity, so low-grade material can pass a total-K2 test while underdelivering on efficacy [9].

**Q: Which EU health claims can products in the Vitamin K2 Market legally carry?**
A: Only the authorized vitamin K claims apply: contribution to normal blood clotting and to the maintenance of normal bones. Cardiovascular claims are not authorized, so heart messaging must stay off EU labels [24].

**Q: How do encapsulation choices affect formulation costs in the Vitamin K2 Market?**
A: Encapsulated grades cost more per kilogram but reduce the overage needed to hit label claims in calcium or magnesium tablets. For mineral-heavy formulas, the total cost per stable dose is often lower [23].

**Q: Is vitamin K2 suitable for vegan product lines?**
A: Fermentation-derived MK-7 produced on plant substrates and most synthetic MK-7 qualify as vegan. Buyers should still confirm substrate origin and processing aids with suppliers before making certified claims.

**Q: What should investors watch when evaluating K2 ingredient suppliers?**
A: Watch intellectual property on all-trans synthesis, ownership of clinical datasets, and capacity utilization. These three factors determine pricing power more than headline production volume.

**Q: How do practitioner channels differ from mass retail for K2 brands?**
A: Practitioner channels favor exclusive, clinically referenced ingredient lines and higher doses sold through health professionals. Exclusive supply deals, such as professional-only MK-7 lines, protect margins against price-led retail competition [25].

**Q: What dose levels are typical in finished K2 supplements?**
A: Most consumer products deliver 90–200 mcg of MK-7 per day, with 180 mcg common because it matches the dose used in key bone studies [4]. Pharmaceutical MK-4 regimens use milligram-level doses under medical supervision.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/vitamin-k2-market-7495*